+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cardiac Arrest Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997396
  • Report
  • March 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4


  • Abbott Laboratories
  • Amgen Inc
  • GE Healthcare
  • Johnson & Johnson
  • Koninklijke Philips N.V
  • Medtronic plc
  • MORE
The Cardiac Arrest Treatment Market studied was anticipated to grow with a CAGR of nearly 4.8% during the forecast period. The major factors driving the growth of the market are the increasing prevalence of various coronary heart diseases, cardiomyopathy which is leading to cardiac arrest deaths, favourable reimbursement initiatives and rise in geriatric population. For instance, according to Global Health And Wellness Report published in 2018, nearly 40% of the adult population in United States were diagnosed with a cardiovascular condition in the United States which directly resulted in higher demand for highly efficient, immediate treatment, and better technological advanced cardiovascular devices to save the life of the patients fueling the growth of the market throughout the forecasted period.

Key Market Trends

The Drug Segment is Expected to Hold the Largest Market Share in the Cardiac Arrest Treatment Market
  • The drugs segment is expected to witness the largest market share in the cardiac arrest treatment market during the forecast period. This dominance is due to the increased use of various drugs such as anti-cholinergics, beta blockers, vasopressors, and fibrinolytic drugs owing to the rise in prescriptions by the cardiologists.
  • Futhermore, anti-arrhythmic drugs are widely used by the most of patients for the treatment of potential arrhythmia and in the emergency period to save the person from heart failure or cardiac arrest. On the other hand, medical devices such as defibrillators and cardiac resynchronization therapy (CRT) are gaining attraction in the recent years and are anticipated to witness a significant growth in the forecast period due to rising awareness among the patients. Furthermore, the growth can be attributed to the rise in usage by the people who are expected to face cardiac arrest problem in the near future.
North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall cardiac arrest treatment market throughout the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications like CAD, strokes and atrial fibrillation along with the rise in chronic diseases such as diabetes & obesity necessitating efficient cardiac arrest treatment. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases among which CAD was the major cause of death resulted in higher demand for better treatment technologies driving the market in the United States contributing to the outstanding share of revenue propelling the global cardiac arrest treatment market throughout the forecasted period.

Competitive Landscape

The cardiac arrest market is moderately competitive and consists of several major players. Few of the key players are developing the novel product and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in January 2017, Abbott acquired St. Jude Medical, expanded its medical device segment globally by adding breakthrough inventions of SJM to its existing product portfolio of cardiovascular devices such as the Quadra Allure MP CRT-P, used as cardiac resynchronization therapy in managing cardiac failure which is further expected to foster the global cardiac arrest market growth throughout the forecast period. Some of the companies which are currently dominating the market are Koninklijke Philips N.V, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, and Novartis AG.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Abbott Laboratories
  • Amgen Inc
  • GE Healthcare
  • Johnson & Johnson
  • Koninklijke Philips N.V
  • Medtronic plc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Global Prevalence of Cardiac Disorders such as Strokes and Coronary Heart Failures
4.2.2 Availability of Technologically Advanced Products and Reimbursement Policies
4.3 Market Restraints
4.3.1 Adoption of Minimally Invasive Procedures like Percutaneous Coronary Interventions
4.3.2 Lack of Advanced Healthcare Infrastructure, Skilled Professionals and Highly Expensive Treatments
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment
5.1.1 Drugs Vasopressors Anti-arrhythmic Drugs Anticholinergic Drugs Antihypertensives Others
5.1.2 Medical Devices Cardiac Resynchronization Therapy (CRT) Defibrillators Others
5.2 By Distribution Channel
5.2.1 Hospitals
5.2.2 Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America United states Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Koninklijke Philips N.V
6.1.2 Boston Scientific Corporation
6.1.3 GE Healthcare
6.1.4 Abbott Laboratories
6.1.5 Novartis International AG
6.1.6 Johnson & Johnson
6.1.7 Pfizer Inc.
6.1.8 Amgen Inc
6.1.9 METsis Medikal
6.1.10 Medtronic plc

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Koninklijke Philips N.V
  • Boston Scientific Corporation
  • GE Healthcare
  • Abbott Laboratories
  • Novartis International AG
  • Johnson & Johnson
  • Pfizer Inc.
  • Amgen Inc
  • METsis Medikal
  • Medtronic plc
Note: Product cover images may vary from those shown